Inhibrx Current ratio
Что обозначает Current ratio в Inhibrx?
Current ratio Inhibrx, Inc. является 6.20
Какое определение для Current ratio?
Коэффициент текущей ликвидности - это коэффициент ликвидности, который измеряет, достаточно ли у компании ресурсов для выполнения своих краткосрочных обязательств.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio компаний в Health Care сектор на NASDAQ по сравнению с Inhibrx
Что делает Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Компании с current ratio похож на Inhibrx
- Geotech имеет Current ratio из 6.19
- Tiltrenew Fpo Nzx имеет Current ratio из 6.19
- Shriram City Union Finance имеет Current ratio из 6.19
- Lightspeed POS имеет Current ratio из 6.19
- Lightspeed POS имеет Current ratio из 6.19
- Osisko Mining имеет Current ratio из 6.20
- Inhibrx имеет Current ratio из 6.20
- Dolly Varden Silver имеет Current ratio из 6.20
- Beijing Hotgen Biotech Co имеет Current ratio из 6.20
- Kismet Resources имеет Current ratio из 6.20
- Host Hotels & Resorts имеет Current ratio из 6.20
- Host Hotels & Resorts Inc имеет Current ratio из 6.20
- Fastned B.V имеет Current ratio из 6.20